894353-16-3Relevant academic research and scientific papers
NOVEL CRYSTALLINE POLYMORPHS OF CLOPIDOGREL
-
Page/Page column 13, (2010/02/11)
The present invention relates to novel crystalline forms of the platelet aggregation inhibitor (+)-(S)-methyl-2-(2-chlorophenyl)-(6,7-dihydro-4H-thieno[3,2-c]pyrid-5-yl)acetate, clopidogrel (1), in the form of hydrogen bromide salts, identified as polymorph forms 1, 2 and 3. The present invention further relates to processes for preparing such forms, pharmaceutical compositions comprising such forms, and uses for such forms and compositions. The pharmaceutical compositions may be used, in particular, for inhibiting platelet aggregation or for treating, preventing or managing thrombosis, atherothrombosis, an atherothrombotic event, ischaemic stroke, myocardial infarction, non-Q-wave myocardial infarction, atherosclerosis, peripheral arterial disease, or unstable angina. The present invention also relates to methods of treating said disorders. Formula (1).
POLYMORPHIC FORMS OF METHYL (+) - (S) -ALPHA- (2-CHLOROPHENYL) -6, 7-DIHYDROTHIENO `3,2-C!PYRIDINE-584H) ACETATE HYDROBROMIDE, CLOPIDROGEL HYDROBROMIDE
-
Page/Page column 5, (2008/06/13)
The invention relates to polymorphic Forms B, C, and D of methyl(+)-(S)-α-(2-chlorophenyl)-6,7-dihydrothieno[3,2-C]pyridine-5(4H) acetate hydrobromide, to pharmaceutical compositions containing the same, and to the method of use thereof for inhibiting platelet aggregation.
